Keywords
Pulmonary Medicine ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

597 Search results.

Screening - GSK Milveterol COPD 100527

- 6/18/17 - 1 form, 9 itemgroups, 132 items, 1 language
Itemgroups: Inclusion/Exclusion criteria, Demography, Duration of Asthma, Vital Signs, 12-Lead Electrocardiogram, Pulmonary function, Hematology, Clinical Chemistry, Urinalysis
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

clinic internal medicine B SHIP-3 operational data lung function

- 10/30/19 - 1 form, 1 itemgroup, 58 items, 2 languages
Itemgroup: operational data lung function
operational data lung function form of SHIP Study (Study of Health in Pomerania), conducted by the University Medicine of Greifswald. SHIP unique domain name SHIP.SHIP3.IMB.LUF.LUFOPD. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617 The English version of this form is under development.

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Non-Serious Adverse Event; Serious Adverse Events; Concomitant Medications

- 10/30/19 - 1 form, 15 itemgroups, 105 items, 1 language
Itemgroups: Non-Serious Adverse Event, Serious Adverse Event, SAE - Type of Report, SAE- Randomisation, SAE - Seriousness, SAE - Relevant Concomitant Medications, SAE - Relevant Medical Conditions/ Risk Factors, SAE - Relevant Diagnostic Results, SAE - Rechallenge, SAE - Investigational Product, SAE - Investigational Product, SAE - Investigational Product , SAE - General Narrative Comments, SAE - Non clinical, Concomitant Medications
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837 - Concomitant Medications Form

- 10/30/19 - 1 form, 1 itemgroup, 22 items, 1 language
Itemgroup: Concomitant Medication Details
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma

CRB-65-Index

- 10/28/19 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: CRB-65-Index
The CRB-65-Score is a clinical score to estimate the severity of a community acquired pneumonia. An outpatient therapy is likely to occur in patients with low risk (CRP-65/CURB = 0 Points). Taking other risk factors into account, patients with a CRB-65/CURB score higher than 1 should be considered to get hospitalised Source: Lim WS, Van Der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82. Der CRB-65-Score ist ein klinisches Instrument um die Schwere einer ambulant erworbenen Pneumonie einzuschätzen. Patienten mit niedrigem Risiko (CRB-65 / CURB = 0) können meistens ambulant behandelt werden. Ab CRB-65 / CURB = 1 sollte unter Einbeziehung anderer Risikofaktoren die stationäre Aufnahme erwogen werden.

CURB-Index

- 10/28/19 - 1 form, 1 itemgroup, 4 items, 1 language
Itemgroup: CURB-Index
The CURB-Score is a clinical score to estimate the severity of a community acquired pneumonia. An outpatient therapy is likely to occur in patients with low risk (CRP-65/CURB = 0 Points). Taking other risk factors into account, patients with a CRB-65/CURB score higher than 1 should be considered to get hospitalised Source: Lim WS, Van Der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82. Der CURB-Score ist ein klinisches Instrument um die Schwere einer ambulant erworbenen Pneumonien einzuschätzen. Patienten mit niedrigem Risiko (CRB-65 / CURB = 0) können meistens ambulant behandelt werden. Ab CRB-65 / CURB = 1 sollte unter Einbeziehung anderer Risikofaktoren die stationäre Aufnahme erwogen werden.

Pneumonia severity index (PSI)

- 10/28/19 - 1 form, 3 itemgroups, 28 items, 1 language
Itemgroups: Characteristics, Risk factors for Risk Group 1 (Tab.1), Classification
The pneumonia severity index (PSI) is a clinical prediction rule to calculate the probability of morbidity and mortality among patients with community acquired pneumonia. Patients in risk group I - III (<70 - 90 points) can be considered to get an outpatient therapy. Patients in risk group IV or V (91- >130 points) should be treated in hospital. More information can be found at http://dev.capnetz.de/html/practitioners/cap/grades/psi?devsid=6f279409536bf424b12899f1ddc330fa Source: Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336:243-250 Der PSI erlaubt eine sichere Klassifizierung in Patienten mit einem niedrigen Letalitätsrisiko (Risikoklassen I – III, maximal 3% Letalität), mit erhöhtem Risiko (Risikoklasse IV, ca. 8% Letalität) sowie Patienten mit einem hohen Risiko (Risikoklasse V, ca. 35% Letalität) und ermöglicht eine risikoadaptierte Auswahl des Behandlungsortes sowie die Identifizierung derjenigen Patienten, die mit einem minimalen Risiko ambulant behandelt werden können.

Eligibility Carcinoma, Non-Small-Cell Lung NCT01897480

- 10/28/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations; ODM derived from: https://clinicaltrials.gov/show/NCT01897480

Eligibility Carcinoma, Non-Small-Cell Lung NCT01261299

- 10/28/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01261299

Eligibility Carcinoma, Non-Small-Cell Lung NCT01199068

- 10/28/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT01199068

Eligibility Carcinoma, Non-Small-Cell Lung NCT01199055

- 10/28/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT01199055

Eligibility Carcinoma, Non-Small Cell Lung NCT00768755

- 10/28/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00768755